An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
about
Sargramostim (GM-CSF) for induction of remission in Crohn's diseaseThe Dual Role of Neutrophils in Inflammatory Bowel DiseasesGrowth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility.Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.Crohn's disease: innate immunodeficiency?Reduced expression of basal and probiotic-inducible G-CSF in intestinal mononuclear cells is associated with inflammatory bowel disease.Current and emerging drugs for the treatment of inflammatory bowel disease.G-CSF preferentially supports the generation of gut-homing Gr-1high macrophages in M-CSF-treated bone marrow cells.Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease.Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.Evolving knowledge and therapy of inflammatory bowel disease.Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro.Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006.Inflammatory bowel disease: past, present, and futureInnovative therapeutics for inflammatory bowel diseaseRecent advances in the medical therapy of Crohn's disease in childhood.Innate immunity in inflammatory bowel disease.Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor.Massive but selective cytokine dysregulation in the colon of IL-10-/- mice revealed by multiplex analysis.Emerging treatments for complex perianal fistula in Crohn's diseaseSargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials.The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases.Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease.Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: A systematic review and meta-analysisNew treatment options in the management of IBD - focus on colony stimulating factors.Is Crohn's disease due to defective immunity?Treatment of Crohn's disease with colony-stimulating factors: An overview.Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells.Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease.Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis.Mobilization without immune depletion fails to restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.Recombinant human granulocyte colony-stimulating factor reduces colonic epithelial cell apoptosis and ameliorates murine dextran sulfate sodium-induced colitis.The anti-inflammatory role of granulocyte colony-stimulating factor in macrophage-dendritic cell crosstalk after Lactobacillus rhamnosus GR-1 exposure.A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: Toward applications for Crohn's disease
P2860
Q24235068-097E46AE-E9FC-471B-8854-D03A2425E2B7Q28080144-76FAE387-7467-4795-AAD8-CFB4926FF7D3Q33738131-EC6F1F8C-B30E-4BC8-A29A-BBD2BE201B15Q34098754-5126AEAE-FBB7-4FDE-8261-153EDB6F2438Q34581819-56843A08-A051-4363-9FE2-A83F8FA3D21DQ34601391-4607CEF0-D278-4739-BD65-E12E6141CB5EQ34883210-BB001459-E6C4-47E7-A197-E0D9AB32744BQ35198809-3E2CDA2B-DC7A-4631-A4C1-6E471A62155BQ35580140-DC2FFC53-5CF0-48F2-8634-496DA996AB58Q35933419-876CEC73-F5A8-401A-88F0-D81D6073339CQ36414506-F5D49C3E-C7A8-4EAC-999B-FDA1C7E314B1Q36500685-EA55327C-6F90-47E2-8F4C-03D4E51110C3Q36739682-54EA0FBE-65C1-4079-A1BD-043DF0ABB3DBQ36745440-1926500A-9AEC-4658-91FA-F38CAB1A6BB5Q36802524-C3C8C3D2-04DC-4E69-9D13-88CA1A813FC5Q36968175-4EE939AF-73E9-4B5B-BDFC-73A28969280CQ36975932-D0E923B2-3A3D-469A-87C3-875EEAF83F6AQ37110990-AF56512E-8708-4CC4-A32D-63676AE843BCQ37372628-B1867B22-29F8-49A6-B7C2-F160B6816CBDQ37596324-2232E3D5-E36A-448A-AD46-04A982CF173FQ38007115-CC4D6177-138D-4ADF-B487-2F9B22652922Q38132555-257CEDE6-BDF7-443F-B194-2D3C3A40086EQ38185880-A9B315A0-3B88-4242-8D44-7C3D831111A4Q39402706-67E632F2-6BCD-42DD-9D51-938798C9BC2EQ42206092-5206BEED-D185-4668-A17A-3B91C8A62C01Q42843695-C746C618-AD19-4295-B050-CEEE368C5508Q43203199-225B829A-356A-4645-BE41-A1750A7A3657Q43639621-3DDCE3E8-1370-4664-A6DF-82E53607BD6DQ47328767-28629B79-2C49-4F20-A314-748946789D37Q50689698-EAF02981-856C-42A2-8916-5953F9191174Q50702410-E232DDA7-E679-43C3-9A32-467286378314Q51697440-D5BBD787-F032-4247-943A-128266666C85Q54384079-C89F3B75-F4AC-489D-BC85-3172B3465013Q58126740-3385D667-2F08-4A6D-A443-D16D6C169AD5
P2860
An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
An open-labelled study of gran ...... ent of active Crohn's disease.
@en
An open-labelled study of gran ...... ent of active Crohn's disease.
@nl
type
label
An open-labelled study of gran ...... ent of active Crohn's disease.
@en
An open-labelled study of gran ...... ent of active Crohn's disease.
@nl
prefLabel
An open-labelled study of gran ...... ent of active Crohn's disease.
@en
An open-labelled study of gran ...... ent of active Crohn's disease.
@nl
P2860
P1476
An open-labelled study of gran ...... ent of active Crohn's disease.
@en
P2093
Dieckgraefe BK
Korzenik JR
P2860
P304
P356
10.1111/J.1365-2036.2005.02287.X
P407
P577
2005-02-01T00:00:00Z